Bayer and Hua Medicine, a Shanghai-based drug development company, announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China.
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 Diabetes. Hua paid $2 million to Roche in 2011 for its global development and marketing rights, and has since spent around $150 million to bring it to phase three trial, the results of which were announced in June.
Bayer has agreed to pay Hua Medicine $43 million upfront and additional payments up to $602 million if milestones are met. Under the terms of the agreement, Hua will be responsible for clinical development, registration, product supply and distribution, while Bayer will be responsible for marketing, promotion and medical education activities in China.
Read the press release
